Sanofi-Aventis' Menactra Demonstrates Noninferiority To Menomune, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The meningococcal vaccine Menactra met its primary safety endpoint of noninferiority in severe systemic adverse events. Sanofi-Aventis failed to show lot consistency within predefined equivalence limits, FDA says.